Stromal Cells for GVHD Prevention
Interferon γ-Primed Mesenchymal Stromal Cells as Prophylaxis for Acute Graft v Host Disease After Allogeneic Hematopoietic Cell Transplantation for Patients With Hematologic Malignancies and Myelodysplasia
More Information
- Trial Status
- Not currently accepting
- Trial Phase
- Phase 1
- Enrollment
- 45 patients (estimated)
- Sponsors
- Ossium Health, Inc.
- Collaborators
- Winship Cancer Institute
- Tags
- Post-Allogeneic Stem Cell Transplant
- Trial Type
- Supportive
- Last Update
- 2 weeks ago
- SparkCures ID
- 1547
- NCT Identifier
- NCT04328714
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.